In the opening episode, Professor Maria Fleseriu and Professor Shlomo Melmed discuss the development of the consensus recommendations and explore how remission and disease control should be defined and assessed in clinical practice. They also highlight the importance of identifying and managing comorbidities, a key focus of the updated recommendations. Please note, this educational podcast series is intended for US healthcare professionals only.
Listen to the audio version of the podcast here or download it from your favorite podcasting platform.
This educational podcast series is intended for US healthcare professionals only. It was developed by expert faculty in collaboration with The Pituitary Society and Amiculum, with support from Recordati Rare Diseases through an independent educational grant. Recordati Rare Diseases had no involvement in content development, speaker selection, or editorial decisions. Discussions in this series are informed by the 2025 consensus on therapeutic outcomes in acromegaly (Melmed S et al. Nat Rev Endocrinol 2025;21:718–37).
Speaker disclosures:
Maria Fleseriu (Oregon Health and Science University, Portland, USA). Research grants to her university from Crinetics Pharmaceuticals and Debio. Scientific consulting fees from Crinetics Pharmaceuticals, Camurus AB, Marea and Recordati Rare Diseases.
Shlomo Melmed (Cedars-Sinai Pituitary Center, Los Angeles, USA). Consulting honoraria and speaker fees from Camurus AB, Marea Therapeutics, Novo Nordisk and Recordati Rare Diseases.
© 2026, J D Faccinetti. All rights reserved.